“All vaccine candidates including Sputnik”
Pfizer supply delay observation
Authorities “There is no change in the first quantity introduction plan”
Final decision on Astra approval on the 10th
Astra comes into Korea from the 24th
The Center for Disease Control and Prevention (center), head of the Corona 19 Vaccination Response Promotion Team, was asked by the National Communication Team at a special briefing on the participatory of the citizens to ask and answer questions related to COVID-19 vaccination held at the Centers for Disease Control and Prevention in Cheongju, Chungbuk on the afternoon of the 8th. have. yunhap news
There are observations that the introduction of 60,000 Pfizer vaccines, known as the first Corona 19 vaccine to be introduced in Korea, may be later than mid-month. The quarantine authorities plan to review the introduction of the Russian vaccine without excluding the possibility of delaying the introduction of the vaccine and the spread of the mutant virus. The first of the 10 million contracts signed with AstraZeneca, the first 750,000 people, is expected to arrive from the 24th of this month. When asked about the timing of the introduction of Pfizer’s vaccine in Korea at a briefing on the 8th, Chung Eun-kyung said, “As the first step, a contract should be made between Covax Facility (World Vaccine Joint Purchase Association) and Pfizer. Accordingly, there is room for some adjustments in the supply schedule. There are procedures left that are difficult for us to control.” It was said that 60,000 Pfizer vaccines (117,000 doses), which Kovax decided to supply to Korea, will be available as early as mid-month. However, depending on the pace of contracts between Kovacs and Pfizer and negotiations between Pfizer and the Korean government, it may be delayed. However, the Agency for Disease Control and Prevention emphasized, “We have not officially changed the schedule of introduction after notifying the Korean government of the schedule that KOVAX will introduce in mid-February.” Commissioner Jeong Eun-kyung said, “Because there are uncertainties such as mutant virus and vaccine supply (delayed) issues, there is a need to continue securing additional vaccines. We will consider all vaccines including Russian Sputnik vaccine as candidates.” Although it is not in discussions with the Russian side about the quantity and schedule of introduction in detail, the possibility of review is open. Previously, the Korea Disease Administration had a position that’the introduction of a vaccine in Russia is not yet under consideration. The approval of the AstraZeneca vaccine, which is controversial about the efficacy of the elderly, is decided through the final inspection committee of the Ministry of Food and Drug Safety on the 10th. On that day, Prime Minister Jeong Sye-gyun said in a question about the education, society, and culture of the National Assembly, “Vaccines will be available on the 24th, and we expect that vaccinations will begin immediately with thorough preparations before that.” Shortly after this remark, the Korea Disease Administration explained that the vaccine was made by AstraZeneca. Commissioner Chung said, “(Regarding the controversy on the efficacy of the elderly), we know that we have requested additional data on the effect through the British authorities and AstraZeneca.” Choi Won-seok, a professor at Korea University’s Ansan Hospital (infectious medicine clinic), said, “We believe that it will be possible to obtain data to confirm statistical significance over time.” “We need to judge the current situation and judge comprehensive things such as vaccines available in Korea “It is done.” By Choi Ha-yan, staff reporter [email protected]